NEXUS Trademark

Trademark Overview

On Thursday, February 2, 2023, a trademark application was filed for NEXUS with the United States Patent and Trademark Office. The USPTO has given the NEXUS trademark a serial number of 97778407. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, September 9, 2025. This trademark is owned by Landos Biopharma, Inc.. The NEXUS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the field of therapeutics, namely, restoring the immune tolerance for patients with autoimmune disease
nexus

General Information

Serial Number97778407
Word MarkNEXUS
Filing DateThursday, February 2, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, September 9, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 15, 2025

Trademark Statements

Goods and ServicesResearch and development in the field of therapeutics, namely, restoring the immune tolerance for patients with autoimmune disease

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, February 21, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameLandos Biopharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRoanoke, VA 24012
Party NameLandos Biopharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRoanoke, VA 24012

Trademark Events

Event DateEvent Description
Tuesday, February 7, 2023NEW APPLICATION ENTERED
Tuesday, February 21, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, August 7, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, August 7, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, August 7, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, October 31, 2023ASSIGNED TO EXAMINER
Monday, November 6, 2023NON-FINAL ACTION WRITTEN
Monday, November 6, 2023NON-FINAL ACTION E-MAILED
Monday, November 6, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 2, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 2, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 2, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 3, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, January 3, 2024SUSPENSION LETTER WRITTEN
Wednesday, January 3, 2024LETTER OF SUSPENSION E-MAILED
Monday, January 6, 2025SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Friday, June 13, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 9, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 15, 2025PUBLISHED FOR OPPOSITION
Tuesday, July 15, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 9, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT

Related Keywords

nexus tolerance patients autoimmune disease immune restoring development field therapeutics namely